Post-ERCP pancreatitis

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 1, 2010, Pages 70-78

  Arata, Shinju ^a   Takada, Tadahiro ^b   Hirata, Koichi ^c   Yoshida, Masahiro ^d   Mayumi, Toshihiko ^e   Hirota, Morihisa ^f   Yokoe, Masamichi ^g   Hirota, Masahiko ^h   Kiriyama, Seiki ⁱ   Sekimoto, Miho ^j   Amano, Hodaka ^b   Wada, Keita ^b   Kimura, Yasutoshi ^c   Gabata, Toshifumi ^k   Takeda, Kazunori ^l   Kataoka, Keisho ^m   Ito, Tetsuhide ⁿ   Tanaka, Masao ⁿ  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^h KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

ⁱ OGAKI MUNICIPAL HOSPITAL   (Japan)

^j KYOTO UNIVERSITY   (Japan)

^k KANAZAWA UNIVERSITY   (Japan)

^l SENDAI CITY MEDICAL CENTER   (Japan)

^m Otsu Municipal Hospital   (Japan)

ⁿ KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Complications; ERCP; Guidelines; Pancreatitis; Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; DICLOFENAC; GABEXATE MESILATE; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PLACEBO; SEMAPIMOD; SOMATOSTATIN; STEROID; ULINASTATIN; GABEXATE; HORMONE; HYDRAZONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ACUTE PANCREATITIS; AGE DISTRIBUTION; ARTICLE; BILE DUCT DILATATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK PATIENT; HUMAN; ODDI SPHINCTER; PATHOLOGICAL ANATOMY; POST ERCP PANCREATITIS; PROPHYLAXIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; STENT; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; META ANALYSIS; PANCREATITIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GABEXATE; HORMONES; HUMANS; HYDRAZONES; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS AS TOPIC; PANCREATITIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SOMATOSTATIN; STENTS;

EID: 77956077901     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-009-0220-5     Document Type: Article

References (59)

1. Takada T, Kawarada Y, Hirata K, et al. JPN Guidelines for the management of acute pancreatitis: Cutting-edge information. J Hepatobiliary Pancreat Surg. 2006;13:2-6. (Pubitemid 43193668)
2. Takada T, Hirata K, Mayumi T, Yoshida M, Tanaka M, Shimosegawa T, et al. JPN guidelines for the management of acute pancreatitis. 3rd ed. JPN Guidelines 2010 (in Japanese). Tokyo: Kanehara; 2009.
3. Centre for Evidence-based Medicine Homepage. Levels of evidence and grades of recommendations. http://www.cebm.net/ levels-of-evidence.asp#levels) 2009.
4. Takada T, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, et al. Cutting-edge information for the management of acute pancreatitis. J Hepatobiliary Pancreat Surg. 2009. doi:10.1007/ s00534-009-0216-1.
5. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc. 1991;37:383-93. (Diagnostic level 5).
6. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: Prospective multicenter study. Gastrointest Endosc. 1998;48:1-10. (Treatment level 2b). (Pubitemid 28337421)
7. Lenriot Aurc JP, Le Neel JC. Catheteisme retrograde et sphincterotomie endoscopique: Evaluation prospective en milieu chirurgical (in French). Gastroenterol Clin Biol. 1993;17:244-50. (Treatment level 2b).
8. Reiertsen O, Skjoto J, Jacobsen CD, Rossel AR. Complications of fiberoptic gastrointestinal endoscopy-five years' experience in a central hospital. Endoscopy. 1987;19:1-6. (Treatment level 2b). (Pubitemid 17232636)
9. Sherman S, Hawes RH, Rathgaber SW, et al. Post-ERCP pancreatitis: Randomized, prospective study comparing a low-and high-osmolality contrast agent. Gastrointest Endosc. 1994; 40:422-7. (Etiologic level 1b). (Pubitemid 24235569)
10. Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: Results of retrospective, multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1995;42:312-6. (Etiologic level 1b).
11. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335: 909-18. (Etiologic level 2b). (Pubitemid 26314443)
12. Escourrou J, Cordova JA, Lazorthes F, Frexinos J, Ribet A. Early and late complications after endoscopic sphincterotomy for biliary lithiasis with and without the gall bladder in situ. Gut. 1984;25:598-602. (Etiologic level 4). (Pubitemid 14122124)
13. Weinberg BM, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev. 2006;18: CD004890. PMID17054222 (Etiologic level 1a).
14. Atomi Y, Saisyo H, Hayakawa T, Akashi R, Kumada T, Shiratori K, et al. A study of endoscopic papillary treatment: A research study of intractable pancreatic diseases, vol. 12. Study by the Ministry of Health, Labour and Welfare of Heisei; 2001. p. 47-53 (Etiologic level 4).
15. Tsujino T, Isayama H, Komatsu Y, et al. Risk factors for pancreatitis in patients with common bile duct stones managed by endoscopic papillary balloon dilation. Am J Gastroenterol. 2005;100(1):38-42. (Etiologic level 4). (Pubitemid 41623266)
16. Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: A meta-analysis. Endoscopy. 2003;35(10):830-4. (Etiologic level 2a). (Pubitemid 37254216)
17. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology. 1991; 101(4):1068-75. (Etiologic level 2b).
18. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: Increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol. 1994;89(3):327-33. (Etiologic level 2b). (Pubitemid 24074388)
19. Dickinson RJ, Davies S. Post-ERCP pancreatitis and hyperamylasaemia: The role of operative and patient factors. Eur J Gastroenterol Hepatol. 1998;10(5):423-8. (Etiologic level 2b). (Pubitemid 28241430)
20. Deans GT, Sedman P, Martin DF, et al. Are complications of endoscopic sphincterotomy age related? Gut. 1997;41(4):545-8. (Etiologic level 2b). (Pubitemid 27448790)
21. De Palma GD, Catanzano C. Use of corticosteroids in the prevention of post-ERCP pancreatitis: Results of a controlled prospective study. Am J Gastroenterol. 1999;94(4):982-5. (Etiologic level 1b). (Pubitemid 29173614)
22. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial. Gastrointest Endosc. 1999; 49(5):593-8. (Etiologic level 1b). (Pubitemid 29227021)
23. Roszler MH, Campbell WL. Post-ERCP pancreatitis: Association with urographic visualization during ERCP. Radiology. 1985;157:595-8. (Etiologic level 4). (Pubitemid 16232093)
24. Johnson GK, Geenen JE, Johanson JF, Sherman S, Hogan WJ, Cass O. Evaluation of post-ERCP pancreatitis: Potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1997;46:217-22. (Etiologic level 1b). (Pubitemid 27424341)
25. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med. 1996;335(13):919-23. (Etiologic level 1b). (Pubitemid 26314444)
26. Singh P, Das A, Isenberg G, Wong RC, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc. 2004;60:544-50. (Treatment/ prevention level 1a). (Pubitemid 39311536)
27. Smithline A, Silverman W, Rogers D, et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc. 1993;39:652-7. (Treatment/prevention level 1b). (Pubitemid 23282518)
28. Sherman S, Bucksot EL, Esber E, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy- induced pancreatitis? Randomized prospective study. Am J Gastroenterol. 1995;90:241. (Treatment/ prevention level 1b).
29. Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology. 1998;115:1518-24. (Treatment/prevention level 1b). (Pubitemid 28546003)
30. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc. 2001;54:209-13. (Treatment/prevention level 2b).
31. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc. 2003;57:291-4. (Treatment/prevention level 1b). (Pubitemid 36350781)
32. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: A comprehensive review. Gastrointest Endosc. 2004;59:845-64. (Treatment/prevention level 5). (Pubitemid 38879313)
33. Sofuni A, Maguchi H, Itoi T, et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol. 2007;5:1339-46. (Treatment/prevention level 1b). (Pubitemid 350019054)
34. Tsuchiya T, Itoi T, Sofuni A. Temporary pancreatic stent to prevent post endoscopic retrograde cholangiopancreatography pancreatitis: A preliminary, single-center, randomized controlled trial. J Hepatobiliary Pancreat Surg. 2007;14:302-7. (Treatment/ prevention level 1b). (Pubitemid 46863921)
35. Freeman ML. Pancreatic stents for prevention of post-endoscopic cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol. 2007;5:1354-65. (Treatment/prevention level 5). (Pubitemid 350019065)
36. Bailey AA, Bourke MJ, Williams SJ, et al. A prospective randomized trial of cannulation technique in ERCP: Effects on technical success and post-ERCP pancreatitis. Endoscopy. 2008;40:296-301. (Treatment/prevention level 1b). (Pubitemid 351524377)
37. Katsinelos P, Paroutoglou G, Kountouras J, et al. A comparative study of standard ERCP catheter and hydrophilic guide wire in the selective cannulation of the common bile duct. Endoscopy. 2008;40:302-7. (Treatment/prevention level 1b). (Pubitemid 351524378)
38. Varadarajulu S, Wilcox CM. Randomized trial comparing needleknife and pull-sphincterotome techniques for pancreatic sphincterotomy in high-risk patients. Gastrointest Endosc. 2006; 64:716-22. (Treatment/prevention level 1b). (Pubitemid 44573116)
39. Khatibian M, Sotoudehmanesh R, Ali-Asgari A, et al. Needleknife fistulotomy versus standard method for cannulation of common bile duct: A randomized controlled trial. Arch Iran Med. 2008;11:16-20. (Treatment/prevention level 1b). (Pubitemid 351233544)
40. Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: A meta-analysis. Hepatobiliary Pancreat Dis Int. 2009;8:11-6. (Treatment/prevention level 1a).
41. Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57:1262-7. (Treatment/prevention level 1a).
42. Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: A complementary meta-analysis. Gut. 2008;57:1632-3. (Treatment/prevention level 1a).
43. Zheng M, Chen Y, Yang X, et al. Gabexate in the prophylaxis of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. BMC Gastroenterol. 2007;7:6-13. (Treatment/prevention level 1a).
44. Rudin D, Kiss A, Wetz RV, et al. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: Meta-analysis of randomized placebo-controlled trials. J Gastroenterol Hepatol. 2007;22:977-83. (Treatment/prevention level 1a). (Pubitemid 47019864)
45. Andriulli A, Leandro G, Federici T, et al. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: An updated meta-analysis. Gastrointest Endosc. 2007;65:624-32. (Treatment/prevention level 1a). (Pubitemid 46442832)
46. Manes G, Ardizzone S, Lombardi G, et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: A randomized, controlled, multicenter study. Gastrointest Endosc. 2007;65:982-7. (Treatment/prevention level 1b). (Pubitemid 46783824)
47. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: A randomized, multicenter controlled trial. Pancreas. 2008;37:445-8. (Treatment/prevention level 1b).
48. Bai Y, Gao J, Zou DW, et al. Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized controlled trials. Pancreas. 2008;37:241-6. (Treatment/prevention level 1a).
49. Zheng M, Chen Y, Bai J, et al. Meta-analysis of prophylactic allopurinol use in post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2008;37:247-53. (Treatment/ prevention level 1a).
50. Bai Y, Gao J, Zhang W, et al. Meta-analysis: Allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther. 2008;28:557-64. (Treatment/prevention level 1a).
51. Zheng M, Bai J, Yuan B, et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastroenterol. 2008;8:6. (Treatment/prevention level 1a).
52. Katsinelos P, Kountouras J, Paroutoglou G, et al. Intravenous Nacetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005;62:105-11. (Treatment/prevention level 1b). (Pubitemid 40922448)
53. Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol. 2006;12:3751-5. (Treatment/ prevention level 1b). (Pubitemid 43950954)
54. Tsujino T, Komatsu Y, Isayama H, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: A randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:376-83. (Treatment/prevention level 1b). (Pubitemid 40488346)
55. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol. 2006;21:1065-9. (Treatment/ prevention level 1b). (Pubitemid 43823296)
56. Ueki T, Otani K, Kawamoto K, et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A prospective, randomized trial. J Gastroenterol. 2007;42:161-7. (Treatment/prevention level 1b). (Pubitemid 46404221)
57. Yoo JW, Ryu JK, Lee SH, et al. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: A prospective, randomized, placebo- controlled trial. Pancreas. 2008;37:366-70. (Treatment/ prevention level 1b).
58. van Westerloo DJ, Rauws EA, Hommes D, et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinase inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastrointest Endosc. 2008;68:246-54. (Treatment/ prevention level 1b). (Pubitemid 352024382)
59. Mine T, Akashi R, Ito T, et al. Progress of a prospective study concerning post-ERCP pancreatitis and its diagnostic criteria; 2008 Report. Tokyo: The intractable pancreatic disease investigation and research group of the Japanese Ministry of Health, Labour and Welfare. 2008. p. 37-43. (Diagnosis level 5).